SIRS 2025 | Posters & Presentations Chicago, IL. USA | 29th March – 2nd April 2025 Be the first to gain access to new data and insights, presented at SIRS 2025. Access Posters Sunday 30th March 12:00-14:00 S162 – Identification of Robust Speech-Based Markers of Negative Symptom Severity in Schizophrenia Spectrum Disorders, by Michael Spilka […]

The post SIRS 2025 | Posters & Presentations appeared first on Cambridge Cognition.

AD/PD 2025 | Posters & Presentations Vienna, Austria | 1st-5th April 2025 Be the first to gain access to new data and insights, presented at AD/PD 2025. Access Posters This year at AD/PD, we can’t wait to share our latest research with you with poster presentations from Emily Thorp, Francesca Cormack and Nick Taptiklis.  2nd-3rd […]

The post AD/PD 2025 | Posters & Presentations appeared first on Cambridge Cognition.

Actigraphy and wearable sensor technologies to enhance assessment in health conditions affecting motor function and behaviour Reflections from the 2025 Actigraph Digital Data Summit​ The 2025 @Actigraph Digital Data Summit in Pensacola, FL, provided a valuable environment for exploring the potential and challenges of using actigraphy, and other wearable sensor technologies, to enhance assessment in […]

The post Actigraphy and wearable sensor technologies to enhance assessment in health conditions appeared first on Cambridge Cognition.

CANTAB® demonstrates substantial value in one of the largest brain health studies ever conducted 6 March 2025 Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, announces its involvement in one of the world’s largest brain health studies, the Intuition Brain Health study1, demonstrating […]

The post CANTAB® demonstrates substantial value in one of the largest brain health studies ever conducted  appeared first on Cambridge Cognition.

Monument Therapeutics secures £850k to advance breakthrough schizophrenia treatment 25 February 2025 Manchester, 25th February 2025 — Monument Therapeutics, an innovative neuroscience company applying digital biomarkers to psychiatric drug development, has secured £850k in further funding led by ACF Investors, with participation from Wren Capital, o2h Ventures, and angel investors. The investment will be used […]

The post Monument Therapeutics secures £850k to advance breakthrough schizophrenia treatment appeared first on Cambridge Cognition.

Cambridge Cognition submits FDA Letter of Intent for Cognitive Impairment Assessments in Schizophrenia 18 February 2025 Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, has submitted a Letter of Intent to the U.S. Food and Drug Administration (FDA) under the Drug Development Tool […]

The post Cambridge Cognition submits FDA Letter of Intent for Cognitive Impairment Assessments in Schizophrenia appeared first on Cambridge Cognition.

ISCTM | 21st Annual Scientific Meeting Washington, D.C., USA | 19-21 February 2025 About the ISCTM The International Society for CNS Clinical Trials and Methodology (ISCTM) is an independent multi-disciplinary organization devoted to promoting advances in, and dissemination of, clinical research methods related to development and use of CNS therapeutics. The ISCTM accomplishes this by […]

The post ISCTM 2025 appeared first on Cambridge Cognition.

Cambridge Cognition Launches In-House Rater Training Digital Measures that Matter Cambridge Cognition is excited to announce a new service that will help transform the quality and efficiency of brain health research. Our new Rater Training service combines with our existing digital tools to create a more streamlined and accurate way to conduct clinical studies focused […]

The post Cambridge Cognition Launches In-House Rater Training appeared first on Cambridge Cognition.

Actinogen Enhances Phase 2b/3 Alzheimer’s Trial with Our Full Digital Suite Digital Measures that Matter Cambridge Cognition is excited to announce the expansion of its partnership with Actinogen Medical Limited for the Phase 2b/3 XanaMILA Alzheimer’s disease trial. Building on the successful integration of Cambridge Cognition’s full product suite including Cognitive Assessments (CANTAB), electronic Clinical […]

The post Actinogen Enhances Phase 2b/3 Alzheimer’s Trial with Cambridge Cognition’s Full Digital Suite appeared first on Cambridge Cognition.

Cambridge Cognition Highlights positive CANTAB® Results in research by Bristol Myers Squib Digital Measures that Matter Cambridge Cognition congratulates Bristol Myers Squibb for its recent FDA approval of Cobenfy (KarXT™ or Xanomeline and Trospium) and the exciting results published recently in The American Journal of Psychiatry1 showcasing the use of CANTAB® in two Phase III […]

The post Cambridge Cognition Highlights positive CANTAB® Results in research by Bristol Myers Squib appeared first on Cambridge Cognition.

Enhancing Patient Outcomes in ADRD Digital Measures that Matter As the landscape for Alzheimer’s Disease and Related Dementias (ADRD) treatment evolves, it’s crucial to align clinical research with the experiences and needs of patients and their care partners. The Digital Medicine Society’s (DiMe) Core Digital Measures of ADRD conceptual model provides a patient-centred framework for […]

The post Enhancing Patient Outcomes in ADRD: Digital Measures that Matter appeared first on Cambridge Cognition.

Exploring Innovation in Alzheimer’s Disease Research Highlights from CTAD 2024 17th Clinical Trials on Alzheimer’s Disease (CTAD) Madrid (Spain) October 29 – November 1, 2024 Last week, our team travelled to Madrid to participate in the 17th Clinical Trials on Alzheimer’s Disease (CTAD) conference, where we had the opportunity to present our latest research and […]

The post Exploring Innovation in Alzheimer’s Disease Research: Highlights from CTAD 2024 appeared first on Cambridge Cognition.

CTAD24 | Posters & Content Madrid, Spain | 29 October – 1 November 2024 This week, our team traveled to Madrid to attend CTAD 2024, where they presented several posters and hosted a session on Validating Speech-Based Biomarkers for Measuring Disease Progression in Alzheimer’s Disease (AD). These materials are now available for you to access […]

The post CTAD24 | Posters & Content appeared first on Cambridge Cognition.

Highlights from the Clinical Trials Innovation Summit 2024 San Francisco, CA – 22nd October 2024 The 2024 Clinical Trials Innovation Summit, hosted by Genentech in San Francisco, gathered experts from across the clinical trial field to reimagine patient care through AI-driven innovation. Featuring industry leaders, clinicians, and researchers this event explored how technological advances and […]

The post Shaping the Future of Patient-Centric, AI-Driven Research appeared first on Cambridge Cognition.

CTAD24 | Clinical Trials on Alzheimer’s Disease Madrid, Spain | 29 October – 1 November 2024 Be the first to gain access to new data and insights, presented at CTAD24. This year at CTAD, we can’t wait to share our latest research with you. There will be four posters, with Michael Spilka, PhD taking us […]

The post CTAD24 | Clinical Trials on Alzheimer’s Disease appeared first on Cambridge Cognition.

Revolutionizing Clinical Trial Central Monitoring: Automated Quality Assurance for Faster, Scalable Monitoring by Rachel Newsome, PhD Tuesday 22nd October at 15:45  Accurate administration of rater-based clinical instruments, such as the Clinical Dementia Rating (CDR), is critical for reliable clinical outcomes in Alzheimer’s Disease (AD) trials. However, existing gold-standard quality assurance (QA) processes rely heavily or […]

The post Clinical Trials Innovation Summit 2024 appeared first on Cambridge Cognition.

We caught up with the 2023 CANTAB® Research Grant Winner, Dr Simran Kaur, from the All India Institute of Medical Sciences, New Delhi, India. She shares with us how the grant will help to non-invasively explore the neural underpinnings to establish state and trait markers in neuropsychiatric and neurodegenerative disorders. I, Dr Simran Kaur sincerely […]

The post 2023 CANTAB Research Grant Winner: Assessment of cognitive function in patients of breast cancer on chemotherapy: A prospective longitudinal study at tertiary care centre in India appeared first on Cambridge Cognition.

We’re thrilled to have presented our latest research at the ISCTM Autumn Meeting on 12-13 September 2024. Rachel Newsome, PhD shared research into the future of clinical trials with recent validation of AQUA, innovation in cognitive assessments, and cutting-edge methodologies. Download poster If you have any questions or would like to discuss any of our […]

The post ISCTM 2024: Analytical validation of a novel quality assurance approach for COAs in Alzheimer’s Disease clinical trials appeared first on Cambridge Cognition.

Cambridge, UK—10 July 2024: Cambridge Cognition, a leading provider of digital health solutions for brain health assessments has been included in the Bio-Hermes-002 project for its voice and touch-screen cognitive assessments, funded by the UK’s innovation agency, Innovate UK.  The Bio-Hermes-002 trial, led by the Global Alzheimer’s Platform Foundation (GAP), aims to determine how accurately digital […]

The post Cambridge Cognition secures Innovate UK grant to collect multimodal data with a large patient sample in the Bio-Hermes-002 project appeared first on Cambridge Cognition.

We’ve joined forces with ESSEXLab at the Centre for Behavioural Science (CBS), University of Essex, to gather normative data from latency-based and rater-scored tasks like our Reaction Time (RTI) task and Verbal Recognition Memory (VRM). This partnership will significantly enrich our normative offerings further and provide robust benchmarks, demonstrating the sensitivity in CANTAB endpoints. Our […]

The post New partnership with the University of Essex to strengthen CANTAB® normative data offering appeared first on Cambridge Cognition.